Clinical Study on Shugan Pingchuan Decoction in the Treatment of Infantile Cough Variant Asthma

OBJECTIVE To observe the clinical effect of Shugan Pingchuan decoction in the treatment of infantile cough variant asthma (CVA). METHODS 88 children with CVA were randomly divided into the treatment group and the control group， and 44 cases in each group. The treatment was intervened by orally taking Shugan Pingchuan granules， and the control group was intervened by orally taking Singulair. Both groups were treated for two weeks. Cough symptoms， TCM syndrome scores， peripheral blood eosinophils (EOS) percentages， serum total immunoglobulin E (total IgE) and Serum interleukin-6 (IL-6) in two groups were compared before and after treatment. RESULTS The curative effects of the treatment group was better than that of the control group (P<0.05). Daytime and night coughing degrees in both groups were better after treatment than those of the pre-treatment， but there was no significant difference between the 2 groups after treatment (P>0.05). Main syndrome scores， secondary syndrome scores and total syndrome scores of both group were improved after treatment compared with those of the pre-treatment (P<0.05). There were significant differences between secondary syndrome scores of 2 groups. The differences of total syndrome scores in two groups were statistically significant (P<0.05)， and the treatment group was better than the control group. Shortness of breath， expectoration， runny nose， sneezing and sleep in the control group were improved compared with those of the pre-treatment， the differences were statistically significant (P<0.05). Shortness of breath， expectoration， runny nose， sneezing， sleep， appetite and defecation in the treatment were improved compared with those of the pre-treatment， the differences were statistically significant (P<0.05， P<0.01). The improvements of expectoration， runny nose， sneezing， appetite and defecation of the treatment group were better than those of the control group (P<0.05， P<0.01). Comparing with the pre-treatment， EOS%， total IgE and IL-6 in both groups were all improved after the treatment (P<0.01)， and the EOS% differences between two groups were statistically significant (P<0.01). CONCLUSION Shugan Pingchuan decoction has satisfactory clinical effect for infantile CVA， which can relieve cough symptoms， improve TCM syndrome and inhibit airway inflammation. And its mechanism is worthy of further study.